Peroxisome proliferator-activated receptors as molecular targets in relation to obesity and type 2 diabetes

Pharmacogenomics

Volumn 8, Issue 6, 2007, Pages 587-596

  Šeda, Ondřej ^a,b,c   Šedova, Lucie ^a,c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Animal models; Ecogenetics; Glitazar; GW501516; Metabolic syndrome; Obesity; Pioglitazone; Rosiglitazone; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BEZAFIBRATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GLIBENCLAMIDE; ISOPROTEIN; METFORMIN; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TRIACYLGLYCEROL; TROGLITAZONE;

ATHEROSCLEROSIS; BONE DEFECT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES CONTROL; DISEASE SEVERITY; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; DYSLIPIDEMIA; ECOLOGICAL GENETICS; EDEMA; EXERCISE; GENE TARGETING; HEART FAILURE; HUMAN; HYPERLIPOPROTEINEMIA; HYPERTENSION; INDIVIDUALIZATION; LIFESTYLE; LIVER FAILURE; LIVER TOXICITY; LOW BIRTH WEIGHT; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; ONTOGENY; OSTEOLYSIS; PHARMACOGENETICS; PHARMACOGENOMICS; PREVALENCE; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SEX DIFFERENCE; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURE ANALYSIS; SYSTEMS BIOLOGY; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-OBESITY AGENTS; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; GENE TARGETING; HUMANS; OBESITY; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; VARIATION (GENETICS);

ANIMALIA;

EID: 34250629658     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.6.587     Document Type: Review

References (75)

1. Hill JO: Understanding and addressing the epidemic of obesity: an energy balance perspective. Endocr. Rev. 27, 750-761 (2006).
2. Seda O, Liska F, Krenova D et al.: Dynamic genetic architecture of metabolic syndrome attributes in the rat. Physiol. Genomics 21, 243-252 (2005).
3. Tuomilehto J, Lindstrom J, Eriksson JG et al.: Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344, 1343-1350 (2001).
4. Knowler WC, Barrett-Connor E, Fowler SE et al.: Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393-403 (2002).
5. Hubacek JA, Pitha J, Skodova Z et al.; Czech MONICA Study: polymorphisms in CYP-7A1, not APOE, influence the change in plasma lipids in response to population dietary change in an 8 year follow-up; results from the Czech MONICA study. Clin. Biochem. 36, 263-7 (2003).
6. Kaput J, Noble J, Hatipoglu B, Kohrs K, Dawson K, Bartholomew A: Application of nutrigenomic concepts to Type 2 diabetes mellitus. Nutr. Metab. Cardiovasc. Dis. 17, 89-103 (2007).
7. Issemann I, Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645-650 (1990).
8. Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W: From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog. Lipid Res. 45, 120-159 (2006).
9. Cresci S: The PPAR genes, cardiovascular disease and the emergence of ppar pharmacogenetics. Expert Opin. Pharmacother. 6, 2577-2591 (2005).
10. Semple RK, Chatterjee VK, O'Rahilly S: PPARγ and human metabolic disease. J. Clin. Invest. 116, 581-589 (2006).
11. Touyz RM, Schiffrin EL: Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vascul. Pharmacol. 45, 19-28 (2006).
12. Brown JD, Plutzky J: Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 115, 518-533 (2007).
13. Zoete V, Grosdidier A, Michielin O: Peroxisome proliferator-activated receptor structures: Ligand specificity, molecular switch and interactions with regulators. Biochim. Biophys. Acta doi:10.1016/ j.bbalip.2007.01.007 (2007) (Epub ahead of print).
14. Michalik L, Auwerx J, Berger JP et al.: International union of pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev. 58, 726-741 (2006).
15. Laudet V: Evolution of the nuclear receptor superfamily: early diversification from an ancestral orphan receptor. J. Mol. Endocrinol. 19, 207-226 (1997).
16. Fajas L, Fruchart JC, Auwerx J: Pparγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoter. FEBS lett. 438, 55-60 (1998).
17. Fajas L, Auboeuf D, Raspe E et al.: The organization, promoter analysis, and expression of the human PPARγgene. J. Biol. Chem. 272, 18779-18789 (1997).
18. Puigserver P: Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1-α. Int. J. Obes. 29(Suppl. 1), S5-S9 (2005).
19. Evans RM, Barish GD, Wang YX: PPARs and the complex journey to obesity. Nat. Med. 10, 355-361 (2004).
20. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W: Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting. J. Clin. Invest. 103, 1489-1498 (1999).
21. Sedova L, Seda O, Krenova D, Kren V, Kazdova L: Isotretinoin and fenofibrate induce adiposity with distinct effect on metabolic profile in a rat model of the insulin resistance syndrome. Int. J. Obes. Relat. Metab. Disord. 28, 719-725 (2004).
22. Haluzik MM, Haluzik M: Ppar-α and insulin sensitivity. Physiol. Res. 55, 115-122 (2006).
23. Keech A, Simes RJ, Barter P et al.: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 366, 1849-1861 (2005).
24. Barter PJ, Rye KA: Cardioprotective properties of fibrates: Which fibrate, which patients, what mechanism Circulation 113, 1553-1555 (2006).
25. Sparso T, Hussain MS, Andersen G et al.: Relationships between the functional ppar[α] leu162val polymorphism and obesity, Type 2 diabetes, dyslipidaemia, and related quantitative traits in studies of 5799 middle-aged white people. Mol. Genet. Metab. 90, 205-209 (2007).
26. Bosse Y, Pascot A, Dumont M et al.: Influences of the PPAR α-l162v polymorphism on plasma HDL(2)-cholesterol response of abdominally obese men treated with gemfibrozil. Genet. Med. 4, 311-315 (2002).
27. Khan QH, Pontefract DE, Iyengar S, Ye S: Evidence of differing genotypic effects of PPAR{α} in women and men. J. Med. Genet. 41, e79 (2004).
28. Foucher C, Rattier S, Flavell DM et al.: Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors α G/C intron7 polymorphism in subjects with Type 2 diabetes. Pharmacogenetics 14, 823-829 (2004).
29. Flavell DM, Ireland H, Stephens JW et al.: Peroxisome proliferator-activated receptor α gene variation influences age of onset and progression of Type 2 diabetes. Diabetes 54, 582-586 (2005).
30. Bernal-Mizrachi C, Weng S, Feng C et al.: Dexamethasone induction of hypertension and diabetes is PPAR-α dependent in LDL receptor-null mice. Nat. Med. 9, 1069-1075 (2003).
31. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology 137, 354-366 (1996).
32. Wang YX, Lee CH, Tiep S et al.: Peroxisome-proliferator-activated receptor Δ activates fat metabolism to prevent obesity. Cell 113, 159-170 (2003).
33. Oliver WR Jr, Shenk JL, Snaith MR et al.: A selective peroxisome proliferator-activated receptor Δ agonist promotes reverse cholesterol transport. PNAS98, 5306-5311 (2001).
34. Sprecher DL, Massien C, Pearce G et al.: Triglyceride:High-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor Δ agonist. Arterioscler. Thromb. Vasc. Biol. 27, 359-365 (2007).
35. Grimaldi PA: Regulatory functions of PPAR[β] in metabolism: Implications for the treatment of metabolic syndrome. Biochim. Biophys. Acta (2007) (Epub ahead of print).
36. Chen S, Tsybouleva N, Ballantyne CM, Gotto AM Jr, Marian AJ: Effects of PPARα, γ and Δ haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. Pharmacogenetics 14, 61-71 (2004).
37. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368, 1096-1105 (2006).
38. Kahn SE, Haffner SM, Heise MA et al.; ADOPT Study Group: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355, 2427-2443 (2006).
39. Benson SC, Pershadsingh HA, Ho CI et al.: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR[γ]-modulating activity. Hypertension 43, 993-1002 (2004).
40. Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW: Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 47, 1003-1009 (2006).
41. Zhang F: Selective modulators of PPAR-γ activity: molecular aspects related to obesity and side-effects. PPAR Res. ID 32696 (2007).
42. Tonjes A, Scholz M, Loeffler M, Stumvoll M: Association of pro12ala polymorphism in peroxisome proliferator-activated receptor-γ with pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 29, 2489-2497 (2006).
43. Seda O, Tremblay J, Sedova L, Hamet P: Integrating genomics and transcriptomics with geo-ethnicity and the environment for the resolution of complex cardiovascular diseases. Curr. Opin. Mol. Ther. 7, 583-587 (2005).
44. Hansen L, Ekstrom CT, Tabanera Y: The pro12ala variant of the PPAR-γ gene is a risk factor for peroxisome proliferator-activated receptor-γ/α agonist-induced edema in Type 2 diabetic patients. J. Clin. Endocrinol. Metab. 91, 3446-3450 (2006).
45. Wolford JK, Yeatts KA, Dhanjal SK et al.: Sequence variation in PPARG may underlie differential response to troglitazone. Diabetes 54, 3319-3325 (2005).
46. Florez JC, Jablonski KA, Sun MW et al.: Effects of the Type 2 diabetes-associated PPAR-γ P12A polymorphism on progression to diabetes and response to troglitazone. J. Clin. Endocrinol. Metab. 92, 1502-1509. (2007).
47. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B: Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145, 401-406 (2004).
48. Grey A, Bolland M, Gamble G et al.: The peroxisome-proliferator-activated receptor-{γ} agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J. Clin. Endocrinol. Metab. 92, 1305-1310 (2007).
49. Roses AD: Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat. Rev. Genet. 5, 645-656 (2004).
50. Nissen SE, Wolski K, Topol EJ: Effect of muraglitazar on death and major adverse cardiovascular events in patients with Type 2 diabetes mellitus. JAMA 294, 2581-2586 (2005).
51. Tenenbaum A, Motro M, Fisman EZ: Dual and pan-peroxisome proliferator-activated receptors (ppar) co-agonism: the bezafibrate lessons. Cardiovasc. diabetol. 4, 14 (2005).
52. Franks PW, Mesa JL, Harding AH, Wareham NJ: Gene-lifestyle interaction on risk of Type 2 diabetes. Nutr. Metab. Cardiovasc. Dis. 17, 104-124 (2007).
53. Lindi VI, Uusitupa MI, Lindstrom J et al.: Association of the pro12ala polymorphism in the PPAR-γ2 gene with 3-year incidence of Type 2 diabetes and body weight change in the Finnish diabetes prevention study. Diabetes 51, 2581-2586 (2002).
54. Robitaille J, Brouillette C, Houde A et al.: Association between the PPARα-l162v polymorphism and components of the metabolic syndrome. J. Hum. Genet. 49, 482-489 (2004).
55. Robitaille J, Gaudet D, Perusse L, Vohl MC: Features of the metabolic syndrome are modulated by an interaction between the peroxisome proliferator-activated receptor-Δ -87t>c polymorphism and dietary fat in French-Canadians. Int. J. Obes. 31, 411-417 (2007).
56. Fritz T, Kramer DK, Karlsson HK et al.: Low-intensity exercise increases skeletal muscle protein expression of PPARΔ and ucp3 in Type 2 diabetic patients. Diabetes Metab. Res. Rev. 22, 492-498 (2006).
57. Kannisto K, Chibalin A, Glinghammar B, Zierath JR, Hamsten A, Ehrenborg E: Differential expression of peroxisomal proliferator activated receptors α and Δ in skeletal muscle in response to changes in diet and exercise. Int. J. Mol. Med. 17, 45-52 (2006).
58. Stefan N, Thamer C, Staiger H et al.: Genetic variations in PPARD and PPARGC1A determine mitochondrial function and change in aerobic physical fitness and insulin sensitivity during lifestyle intervention. J. Clin. Endocrinol. Metab. 92(5), 1827-1833 (2007).
59. Andrulionyte L, Peltola P, Chiasson JL, Laakso M: Single nucleotide polymorphisms of ppard in combination with the gly482ser substitution of pgc-1a and the pro12ala substitution of pparg2 predict the conversion from impaired glucose tolerance to Type 2 diabetes: the stop-niddm trial. Diabetes 55, 2148-2152 (2006).
60. Sedova L, Seda O, Kazdova L et al.: Sucrose feeding during pregnancy and lactation elicits distinct metabolic response in offspring of an inbred genetic model of metabolic syndrome. Am. J. Physiol. Endocrinol. Metab. 292(5), E1318-E1324 (2007).
61. Buresova M, Zidek V, Musilova A et al.: Genetic relationship between placental and fetal weights and markers of the metabolic syndrome in rat recombinant inbred strains. Physiol. Genomics 26, 226-231 (2006).
62. Eriksson JG, Lindi V, Uusitupa M et al.: The effects of the pro12ala polymorphism of the peroxisome proliferator-activated receptor-γ2 gene on insulin sensitivity and insulin metabolism interact with size at birth. Diabetes 51, 2321-2324 (2002).
63. Yliharsila H, Eriksson JG, Forsen T et al.: Interactions between peroxisome proliferator-activated receptor-γ 2 gene polymorphisms and size at birth on blood pressure and the use of antihypertensive medication. J. Hypertens. 22, 1283-1287 (2004).
64. de Rooij SR, Painter RC, Phillips DI et al.: The effects of the pro12ala polymorphism of the peroxisome proliferator-activated receptor-γ2 gene on glucose/insulin metabolism interact with prenatal exposure to famine. Diabetes Care 29, 1052-1057 (2006).
65. Meirhaeghe A, Boreham CA, Murray LJ et al.: A possible role for the PPARG Pro12Ala polymorphism in preterm birth. Diabetes. 56, 494-498. (2007)
66. Barak Y: Genetic manipulations of PPARs: effects on obesity and metabolic disease. PPAR Res. (2007) (Epub ahead of print).
67. Pan HJ, Reifsnyder P, Vance DE, Xiao Q, Leiter EH: Pharmacogenetic analysis of rosiglitazone-induced hepatosteatosis in new mouse models of Type 2 diabetes. Diabetes 54, 1854-1862 (2005).
68. Leiter EH, Reifsnyder PC, Zhang W, Pan HJ, Xiao Q, Mistry J: Differential endocrine responses to rosiglitazone therapy in new mouse models of Type 2 diabetes. Endocrinology 147, 919-926 (2006).
69. Qi N, Kazdova L, Zidek V et al.: Pharmacogenetic evidence that cd36 is a key determinant of the metabolic effects of pioglitazone. J. Biol. Chem. 277, 48501-48507 (2002).
70. Seda O, Sedova L, Kazdova L, Krenova D, Kren V: Metabolic characterization of insulin resistance syndrome feature loci in three brown norway-derived congenic strains. Folia Biol. (Prague) 48, 81-88 (2002).
71. Hamet P, Merlo E, Seda O et al.: Quantitative founder-effect analysis of french canadian families identifies specific loci contributing to metabolic phenotypes of hypertension. Am. J. Hum Genet. 76, 815-832 (2005).
72. Kren V, Krenova D, Bila V, Zdobinska M, Zidek V, Pravenec M: Recombinant inbred and congenic strains for mapping of genes that are responsible for spontaneous hypertension and other risk factors of cardiovascular disease. Folia Biol. (Prague) 42, 155-158 (1996).
73. Churchill GA, Airey DC, Allayee H et al.: The collaborative cross, a community resource for the genetic analysis of complex traits. Nat. Genet. 36, 1133-1137 (2004).
74. Malek RL, Wang HY, Kwitek AE et al.: Physiogenomic resources for rat models of heart, lung and blood disorders. Nat. Genet. 38, 234-239 (2006).
75. Svenson KL, Von Smith R, Magnani PA et al.: Multiple trait measurements in 43 inbred mouse strains captures the phenotypic diversity characteristic of human populations. J. Appl. Physiol. (2007) (Epub ahead of print).